PetMed Express, Inc. (NASDAQ:PETS) has received a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $42.80.

Several equities research analysts have recently commented on the stock. ValuEngine cut shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Credit Suisse Group reaffirmed an “underperform” rating and issued a $19.00 target price on shares of PetMed Express in a research report on Monday, October 2nd. BidaskClub cut shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 19th. Northcoast Research set a $58.00 target price on shares of PetMed Express and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a research report on Friday, October 27th.

PetMed Express (NASDAQ PETS) traded up $1.77 during trading hours on Friday, hitting $47.80. 803,254 shares of the stock traded hands, compared to its average volume of 997,480. PetMed Express has a 12-month low of $19.21 and a 12-month high of $57.80. The stock has a market cap of $957.67, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.73 and a beta of 1.12.

PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, January 22nd. The company reported $0.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.11. PetMed Express had a net margin of 12.84% and a return on equity of 34.04%. The firm had revenue of $60.10 million during the quarter, compared to analysts’ expectations of $56.76 million. During the same period last year, the company posted $0.24 EPS. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. analysts expect that PetMed Express will post 1.7 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Investors of record on Monday, February 5th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 2.09%. This is a positive change from PetMed Express’s previous quarterly dividend of $0.20. The ex-dividend date is Friday, February 2nd. PetMed Express’s dividend payout ratio (DPR) is presently 47.34%.

In related news, Director Gian Fulgoni sold 20,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now directly owns 55,900 shares in the company, valued at approximately $2,480,842. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Menderes Akdag sold 10,000 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $57.00, for a total transaction of $570,000.00. Following the completion of the transaction, the chief executive officer now owns 470,000 shares of the company’s stock, valued at $26,790,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,000 shares of company stock valued at $2,987,600. 4.00% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Pinebridge Investments L.P. increased its stake in PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after purchasing an additional 27 shares in the last quarter. Advisor Group Inc. increased its stake in PetMed Express by 0.7% during the 2nd quarter. Advisor Group Inc. now owns 24,844 shares of the company’s stock valued at $1,009,000 after purchasing an additional 179 shares in the last quarter. QS Investors LLC increased its stake in PetMed Express by 4.0% during the 2nd quarter. QS Investors LLC now owns 9,324 shares of the company’s stock valued at $379,000 after purchasing an additional 356 shares in the last quarter. Thrivent Financial For Lutherans increased its stake in PetMed Express by 7.9% during the 2nd quarter. Thrivent Financial For Lutherans now owns 12,440 shares of the company’s stock valued at $505,000 after purchasing an additional 910 shares in the last quarter. Finally, Cardinal Capital Management increased its stake in PetMed Express by 11.6% during the 3rd quarter. Cardinal Capital Management now owns 12,553 shares of the company’s stock valued at $416,000 after purchasing an additional 1,309 shares in the last quarter. Institutional investors and hedge funds own 99.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/analysts-set-petmed-express-inc-pets-target-price-at-42-80/1826595.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.